Digital Transformation in the Pharmaceutical Industry: Trends and Impact (with abstract)
| Digital Transformation in the Pharmaceutical Industry: Trends and Impact (with abstract) | |
|---|---|
| Published By | Virto_Commerce |
| Publish Date | Jun 6, 2024 |
| Authors | Svetlana Golubeva |
| Topics | B2B eCommerce in Pharma |
| Statistics | |
| Article Size | words |
| Diagrams | No |
| Downloadable Version | No |
| Reviewers | |
| Page Owner | Nikolay Sidelnikov |
| Summary Author | Nikolay Sidelnikov |
Abstract
In the article Digital Transformation in the Pharmaceutical Industry: Trends and Impact, the author examines how pharmaceutical companies approach digital transformation and its impact on drug development, manufacturing, and distribution processes. He also explores the core digital pharma technologies companies use to drive innovation.
Digital technology is transforming key processes in the pharmaceutical industry, particularly in research and development (R&D), manufacturing, and distribution.
- R&D: Companies are using AI to improve drug discovery and clinical development by identifying drug targets more effectively and predicting side effects. Examples include Sanofi, AstraZeneca, and Novartis, which use AI to streamline research and clinical trials.
- Manufacturing: Innovations like Pharma 4.0 (automation, IoT, and AI) are optimizing production. For instance, GlaxoSmithKline uses digital twin technology, while Sanofi employs AI to enhance manufacturing yields.
- Distribution: Blockchain ensures drug authenticity and supply chain transparency, as seen with Merck. Digital pharma commerce platforms also enhance inventory management and order fulfillment, ensuring timely access to medicines.
Digital transformation in the pharmaceutical industry faces several challenges:
- Legacy IT systems: Many pharmaceutical companies operate with outdated systems that are difficult to integrate with modern technologies, hindering seamless digital transformation.
- High costs and ROI concerns: Implementing digital solutions like AI or cloud-based systems requires significant upfront investment, making it hard to justify without clear ROI. Small pilot projects help assess effectiveness before scaling.# Regulatory compliance: New technologies must meet strict regulatory standards to ensure patient safety and data security, which can delay implementation.
- Cultural barriers: Resistance to change within large, established companies requires strong leadership, clear communication, and training to ensure a supportive environment for transformation.
Full article text: https://virtocommerce.com/blog/pharma-digital-transformation
Subscribe to B2B Experts Digest
Contribute to B2B Experts Community
Subscribe to B2B Experts on LinkedIn
Published on LinkedIn: